The Australian diagnostic and therapeutic radiopharmaceutical company reported revenue of $220.8 million, driven by growth in prostate cancer imagined agent Illuccix. …
Telix says result reflects its transition to a sustainable commercial-stage company
August 25, 2023 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Weight loss medicines drive revenue sales growth for Sigma and Wesfarmers Health
August 28, 2026 - - BioPharma -
Patients Australia put healthcare’s quiet achievers in the spotlight
August 28, 2026 - - Latest News -
Cheaper medicines save Australians $1.4 billion as pharmacists urge freeze for all patients
August 28, 2026 - - Latest News -
Mayne Pharma bets on women’s health and direct distribution after a difficult year
August 28, 2026 - - Latest News -
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News -
Australian company secures Mitsubishi partnership to bring BioPQQ to market
August 26, 2026 - - Latest News -
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech